AACR 2024: PDC*line Pharma presents interim clinical results from last cohort of patients in phase I

Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and...

Related Keywords

France ,Switzerland ,Germany ,Belgium ,Netherlands ,Leuven ,Region Flamande ,United States ,Poland ,American ,Johan Vansteenkiste ,Eric Halioua ,American Association For Cancer Research ,Non Small Cell Lung Cancer ,American Association ,Cancer Research ,Annual Meeting ,Low Dose ,High Dose ,Objective Response Rate ,Progression Free Survival ,Adverse Events ,Partial Response ,Stable Disease ,Best Objective Response ,Disease Control Rate ,Not Reached ,Prof Johan Vansteenkiste ,Safety Monitoring Board ,Beatrice De Vos ,Plasmacytoid Dendritic Cells ,Peripheral Blood Mononuclear Cells ,